# Pizarra — PT-pseudo_41ca49bed13d (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_41ca49bed13d
Task: 1

Encounter: Urology - outpatient on 04 Feb 2025.
Referrer: Dr. L. Smits (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 47-year-old male
  - PSA: 14.0 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.734 ng/mL²
  - PSA velocity: 2.79 ng/mL/yr
  - Prior PSA: 12.0 ng/mL
  - Prostate volume: 19.07 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8159218 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 14 ng/mL. PI-RADS 4. PSAD 0.73. Prostate volume 19 mL. DRE nodus. csPCa 0.82.

Vitals: weight 89 kg, height 179 cm, BMI 27.8, BP 135/77 mmHg, HR 82 bpm. Smoking: Non-smoker.

Chief complaint: Evaluation is requested after a PSA increase to 14.0 ng/mL coincides with an MRI revealing a highly suspicious lesion.

History: At 47 years of age, this mechanical engineer underwent initial PSA screening in 2022 and has since tracked his biomarkers through routine blood work. He remains a non-smoker with no regular pharmacological interventions or notable comorbid conditions. A biopsy bucket of "None" applies to his current diagnostic phase. His lifestyle includes commuter cycling five days weekly and roughly nine alcohol units per week. Although married, he resides alone, relying on his spouse for daily support. Lower urinary tract complaints dominate his current presentation, marked by an IPSS score of 27 stemming from nocturia and a diminished urinary stream that heavily disrupts his routine. He occasionally experiences mild fatigue, which he links to occupational stress and a hearing deficit requiring written consultation summaries. A knee arthroscopy performed during his thirties for athletic trauma remains an isolated past event without recent sequelae.

Physical examination: DRE: Digital assessment uncovers an asymmetrically enlarged gland harboring a firm, discrete nodule within the right mid-gland region. Abdominal and cardiovascular surveys show no abnormalities, vital parameters remain stable, and systemic pathology is absent.

Patient info: mechanical engineer; Married; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 9 units / week; exercise Cycling 5x/week (commuter); IPSS score: 27/35 (severe LUTS).


Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.81 +/- 0.09   (95% CI 0.64-0.99)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.09  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.69 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'firm': p +/- 1.96*dp does not cross the 0.5 threshold. Treat it as a strong prior that should only be overturned by explicit contradicting evidence. Measured accuracy in this tier on the labelled cohort: 1.0 over 28 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI prose confirm the PI-RADS 4 finding and provide lesion size/zone comparison?
  - psa_trend (get_psa_trend) -> Does the PSA history show a significant trend or velocity change that warrants immediate action?
  - previous_notes (get_previous_notes) -> What was the prior management context, including prior grade and surveillance pathway?

This case hinges on integrating the high-risk imaging finding (PI-RADS 4) with the patient's PSA trajectory and prior management context to confirm the biopsy recommendation.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, which excluded the prose of the mpMRI report, the PSA trajectory, and the previous notes. Specifically, it did not account for the specific PSA velocity (2.79 ng/mL/yr) or the specific PI-RADS 4 score in conjunction with the prior biopsy status (None).

WHY THE SUGGESTION COULD BE WRONG
The prior suggested BIOPSY with a high probability (0.81). This suggestion could be wrong because the model did not account for the high aleatoric uncertainty ($H=0.69$), indicating the model struggles to distinguish this case. Furthermore, the prior did not weigh the specific clinical conflict: a high csPCa probability (0.8159218) against a DRE finding of "Nodus" (which is ambiguous) and the fact that the guideline suggests omitting biopsy if PSA density is low and no family history exists.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI prose confirm the PI-RADS 4 finding and provide lesion size/zone comparison?
psa_trend - Does the PSA history show a significant trend or velocity change that warrants immediate action?
previous_notes - What was the prior management context, including prior grade and surveillance pathway?
laboratory panel - Does the laboratory panel provide context on PSA density relative to guideline cut-offs?
GUIDELINE ANCHOR
The guideline suggests considering targeted biopsy when MRI is positive (PI-RADS $\ge 4$) and notes that omitting biopsy is an option if PSA density is low and no family history is present.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_41ca49bed13d", "radiology_report": "Subject: Multiparametric MRI Prostate | Date: 28 Jan 2025 | Facility: Tergooi MC\n\nClinical Indication:\nClinical suspicion of prostate malignancy accompanies a PSA reading of 14.0 ng/mL.\n\nFINDINGS:\nProstatic tissue occupies 19.07 mL. T2 sequences highlight a 12 mm focus of hypointensity within the right anterior mid-gland peripheral zone. High b-value DWI shows intense restricted diffusion, mirrored by corresponding ADC hypointensity. DCE sequences capture prompt focal enhancement against adjacent tissue. Capsular integrity remains preserved; neurovascular bundles are spared. No seminal vesicle invasion, extraprostatic spread, suspicious nodal enlargement, or skeletal abnormalities are detected.\n\nIMPRESSION:\nPI-RADS 4\nProstate volume 19.07 mL.\nPSA density 0.734 ng/mL/mL.\ncsPCa predicted probability 0.8159218."}
get_psa_trend
{"case_id": "PT-pseudo_41ca49bed13d", "psa_trend": [{"date": "Aug 2022", "val": 2.3}, {"date": "Jun 2023", "val": 4.2}, {"date": "Apr 2024", "val": 7.7}, {"date": "Feb 2025", "val": 14.0}]}
get_previous_notes
{"case_id": "PT-pseudo_41ca49bed13d", "previous_notes": [{"date": "07 Oct 2024", "author": "Dr. L. Smits (GP)", "text": "Subsequent review highlights a progressive PSA trajectory, climbing from 12.0 ng/mL recorded in April 2024 to 14.0 ng/mL on recent assays. Accompanying deterioration in lower urinary tract symptoms prompted referral for expert consultation and advanced cross-sectional imaging."}]}
NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not explicitly request the full laboratory panel.
WHAT THE EVIDENCE SUPPORTS
FOR Sampling this patient now:
- MRI report: PI-RADS 4 finding with a 12 mm focus of hypointensity in the right anterior mid-gland peripheral zone.
- PSA trend: Significant upward velocity, with PSA increasing from 7.7 ng/mL (Apr 2024) to 14.0 ng/mL (Feb 2025).
- Previous notes: Documented progressive PSA trajectory and referral for advanced imaging.
AGAINST Sampling this patient now:
- MRI report: No evidence of seminal vesicle invasion, extraprostatic spread, or suspicious nodal enlargement.
- Guideline context: The guideline suggests omitting biopsy if PSA density is low and no family history is present.
WHERE THIS LEANS
The evidence strongly supports proceeding with a biopsy due to the high-risk PI-RADS 4 finding and the concerning PSA velocity, aligning with the expert protocol.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence strongly supports proceeding with a biopsy based on the PI-RADS 4 finding and the concerning PSA velocity, aligning with the expert protocol. The laboratory results remain unretrieved, which is noted as missing.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to biopsy is supported by convergence across all inputs. The PI-RADS 4 finding, which is decisive for sampling, was confirmed by the retrieved MRI report detailing a 12 mm focus. This finding aligns with the EXPERT-PROTOCOL criterion, and the rising PSA velocity further supports the need for intervention. The statistical prior also strongly suggested biopsy, and the retrieved evidence confirmed this consensus.

Variables that carried weight: age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
